FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

washington, b.c. 20049

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours nor resnance.	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* BROWN JAMES F				<u>B</u>	2. Issuer Name and Ticker or Trading Symbol BELLICUM PHARMACEUTICALS, INC							 Relationship of Reporting Per (Check all applicable) X Director 				rson(s) to Issuer		
	LICUM PI	HARMACEUTI		3.	BLCM] 3. Date of Earliest Transaction (Month/Day/Year) 06/14/2017								Officer below)	(give title		Other (s below)	specify	
2130 W. HOLCOMBE BLVD., STE. 800 (Street) HOUSTON TX 77030 (City) (State) (Zip)			4.	4. If Amendment, Date of Original Filed (Month/Day/Year)							. Indivine)	ividual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person						
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date) Table II - Derivati				Transaction te onth/Day/Y	tion y/Year) 2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transac Code (I 8) Code	v	4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 5) Amount (A) or (D) P Sed of, or Benefici		ed (A) or str. 3, 4 a Price	nd e	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)	
1. Title of Derivative Security (Instr. 3)	1. Title of Derivative Conversion Date Execution Date, (Month/Day/Year) if any			4. Transa	ansaction ide (Instr. 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Options, convertil 6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amor of Securities Underlying Derivative Secur (Instr. 3 and 4)		nt 8. D S (III	Price of erivative ecurity nstr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	e S Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisabl		Expiration Date	Title	Number of Shares						
Stock Option (right to buy)	\$10.34	06/14/2017		A		10,000		(1)	C	06/13/2027	Common Stock	10,00	0	\$0	10,000	0	D	

Explanation of Responses:

1. The shares subject to the option vest and become exercisable in equal monthly installments until the Issuer's 2018 Annual Meeting of stockholders.

Remarks:

/s/ Ken Moseley, Attorney-in-06/15/2017

Fact

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.